• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients
Infect Disord Drug Targets. 2022 Apr 19. doi: 10.2174/1871526522666220419130403. Online ahead of print.ABSTRACTMore than 200 viruses infect humans but drugs are available for fewer than ten. To narrow the gap between 'bugs and drugs', a paradigm shift is required. The "one drug, one bug" approach should be supplemented by the "one drug, multiple bugs" strategy such that the host is targeted rather than the virus. The revolutionary viral superinfection therapy (SIT) activates the antiviral interferon gene natural defense system of host cells from within by an attenuated infectious bursal disease virus (IBDV) that releases i...
Source: Infectious Disorders Drug Targets - April 20, 2022 Category: Infectious Diseases Authors: Tibor Bakacs Volker Sandig Shimon Slavin Serhat Gumrukcu W David Hardy Wolfgang Renz Imre Kovesdi Source Type: research

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus
Ann Hematol. 2022 Jan 7. doi: 10.1007/s00277-021-04746-y. Online ahead of print.ABSTRACTClinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvi...
Source: Herpes - January 7, 2022 Category: Infectious Diseases Authors: Larissa Henze Christoph Buhl Michael Sandherr Oliver A Cornely Werner J Heinz Yascha Khodamoradi Til Ramon Kiderlen Philipp Koehler Alrun Seidler Rosanne Sprute Martin Schmidt-Hieber Marie von Lilienfeld-Toal Source Type: research

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
Hum Vaccin Immunother. 2021 Dec 14:1-8. doi: 10.1080/21645515.2021.2002085. Online ahead of print.ABSTRACTThe aim of the study was to update previously published public health impact and cost-effectiveness analyses of the recombinant zoster vaccine (RZV), in the German population aged ≥50 years of age (YOA), with the latest vaccine efficacy (VE) estimates against herpes zoster (HZ). The updated estimates are derived from a long-term follow-up study. A previously published multi-cohort Markov model following age cohorts over their lifetime was used. Demographic, epidemiological, cost, and utility data were based on German...
Source: Herpes - December 14, 2021 Category: Infectious Diseases Authors: Desmond Curran Desir ée Van Oorschot Sean Matthews Johannes Hain Ahmed Ehab Salem Magdalena Schwarz Source Type: research

An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
ConclusionThis review of spontaneously reported post-marketing data did not raise safety concerns regarding the occurrence of vesicular and bullous cutaneous eruptions following vaccination with RZV.
Source: Drug Safety - October 7, 2021 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2